Insulet (NASDAQ:PODD) Posts Earnings Results, Beats Estimates By $0.19 EPS

Insulet (NASDAQ:PODD) issued its quarterly earnings data on Wednesday. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.47 by $0.19, FiscalAI reports. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm had revenue of $801.70 million during the quarter, compared to analysts’ expectations of $787.39 million. During the same period last year, the company earned $1.17 earnings per share. The business’s revenue was up 23.5% on a year-over-year basis. Insulet updated its FY 2026 guidance to 6.460- EPS.

Here are the key takeaways from Insulet’s conference call:

• Strong second-quarter performance: Revenue increased 23% on a constant-currency basis to $802 million, while adjusted operating margin expanded 140 basis points to 19.3% and adjusted EPS rose 41.5% to $1.66.
• Insulet lowered its 2026 outlook to 20%–22% total company revenue growth and 17%–19% U.S. Omnipod growth, citing weaker-than-expected type 2 customer retention and utilization, slower new customer starts, and somewhat lower anticipated pricing.
• The company is expanding customer support, revising sales-force incentives to emphasize retention, refining sampling, and scaling Omnipod Discover to improve onboarding and retention during the critical first 90 days of therapy.
• International momentum remains strong, with full-year international Omnipod growth guidance raised to 30%–32%; the company also reported coverage additions for 6.5 million lives and reduced prior-authorization barriers for approximately 10 million lives.
• Insulet continues to invest in its pipeline, including Omnipod 6 and a fully closed-loop type 2 system, with a 510(k) submission for the latter still expected in 2027; formal 2027 guidance and an updated long-range outlook will come with fourth-quarter results.

Insulet Stock Up 1.3%

PODD stock traded up $1.87 during trading on Friday, reaching $141.17. The stock had a trading volume of 1,587,738 shares, compared to its average volume of 1,315,156. The company has a quick ratio of 1.81, a current ratio of 2.48 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $9.78 billion, a price-to-earnings ratio of 26.39, a P/E/G ratio of 0.92 and a beta of 1.10. Insulet has a one year low of $126.40 and a one year high of $354.88. The company’s 50 day moving average is $155.49 and its two-hundred day moving average is $193.97.

Insider Activity at Insulet

In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.36% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PODD. University of Texas Texas AM Investment Management Co. purchased a new stake in shares of Insulet during the 4th quarter valued at $26,000. DV Equities LLC purchased a new position in shares of Insulet in the 4th quarter worth about $28,000. Mcguire Capital Advisors Inc. bought a new position in Insulet during the fourth quarter valued at about $29,000. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its position in Insulet by 68.8% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 135 shares of the medical instruments supplier’s stock valued at $38,000 after buying an additional 55 shares during the period. Finally, Measured Wealth Private Client Group LLC purchased a new stake in Insulet during the third quarter worth about $49,000.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on PODD. TD Cowen cut their price target on Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research note on Thursday. Benchmark lowered their price objective on Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday. Wells Fargo & Company lowered Insulet from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $255.00 to $144.00 in a report on Wednesday. BTIG Research cut Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday. Finally, Truist Financial reiterated a “hold” rating and set a $153.00 price target (down from $210.00) on shares of Insulet in a report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of “Hold” and an average price target of $195.40.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported second-quarter EPS of $1.66, above the $1.47 consensus estimate, while revenue of $801.7 million exceeded expectations and increased 23.5% year over year. Management also maintained a growth narrative for its Omnipod platform despite near-term challenges. Insulet Corporation Q2 2026 Earnings Call Summary
• Positive Sentiment: Benchmark and Stifel retained “buy” ratings despite cutting their price targets to $185 and $180, respectively, implying substantial potential upside from recent levels. Their continued bullish ratings may be supporting the rebound. Analyst Forecasts After Q2 Results
• Neutral Sentiment: Several law firms reminded shareholders of an August 31 deadline to seek lead-plaintiff status in a federal securities class action covering purchases made during portions of February 2025 through May 2026. These announcements largely repeat previously reported litigation rather than disclose a new operational development. ROSEN Securities Class Action Deadline
• Negative Sentiment: Insulet lowered its 2026 revenue outlook after weaker retention among type 2 diabetes users, raising concerns about the durability of Omnipod adoption and second-half growth. The guidance reduction triggered broad analyst target cuts, including TD Cowen to $144, UBS to $150, JPMorgan to $152 and Leerink Partners to $145. Insulet Down After Cutting Revenue Outlook
• Negative Sentiment: The securities lawsuit alleges violations of federal securities laws by Insulet and certain officers, while reports have linked investor concerns to two Omnipod recalls and possible manufacturing, quality-control and regulatory risks. The litigation and reputational overhang remain pressure points for PODD. Pomerantz Class Action Filing

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.